CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026
- Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models
Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it will present a poster, together with the Centre for Genomic Regulation (CRG), on CONNECTA’s lead, first-in-class program, CTH120, at the FENS Forum 2026, taking place 6-10 July 2026 in Barcelona, Spain.
